N ORTION® HIF-PEF Ablation Technology Featured in Leading Medical Journal, Pioneering Breakthrough in BPH Treatment

Recently, groundbreaking research on the NORTION® High-Frequency Irreversible Electroporation (H-FIRE) ablation system—developed independently by NORTION as a global leader in the field—was published in the Urology journal. The study not only validates the exceptional efficacy and safety of H-FIRE technology in treating Benign Prostatic Hyperplasia (BPH), but also provides robust scientific evidence for its clinical adoption."

The published paper, entitled 'Efficacy and Safety of High-frequency Irreversible Electroporation in Benign Prostatic Hyperplasia: A Randomized Controlled, Open-Label, Multicenter Clinical Study', represents yet another landmark for H-FIRE technology in BPH therapy. Led by elite urology teams from Renji Hospital, Tongji Hospital, Shanghai East Hospital, Qilu Hospital of Shandong University, and other leading Chinese institutions, this rigorous randomized controlled trial provides authoritative validation and endorsement for H-FIRE's clinical implementation.

The study results demonstrate exceptional efficacy of H-FIRE technology in treating benign prostatic hyperplasia. Patients in the treatment group exhibited significant improvements in maximum urinary flow rate (Qmax), prostate volume, and International Prostate Symptom Score (IPSS) at 12-month follow-up, with minimal adverse event incidence. Subgroup analysis further confirmed that H-FIRE delivers consistent and clinically meaningful therapeutic outcomes regardless of baseline prostate size.

H-FIRE technology achieves precise ablation of diseased tissue by delivering high-frequency composite steep pulses, while preserving the functionality of surrounding healthy tissues. Compared to conventional treatment methods, H-FIRE technology demonstrates the following significant advantages in treating BPH:

√ Reduced Trauma: Requires only minimally invasive procedures, causing minimal damage to surrounding tissues.

√ Faster Recovery: Patients experience reduced hospital stays and rapid postoperative recovery.

√ Function Preservation: Effectively safeguards urinary continence and sexual function, significantly enhancing patients' quality of life.

√ No Urethral Access: The procedure avoids traversing the urethra, preventing compromise of the urethral mucosa.

This research was published in Urology, a medical journal specializing in Urology & Nephrology published by Elsevier Inc. and indexed in PubMed, providing robust scientific validation for the clinical application of H-FIRE technology. This achievement not only cements Nosaier®'s leadership in high-frequency pulsed field ablation technology but also expands therapeutic options for benign prostatic hyperplasia patients worldwide.

Building on the continuous breakthroughs of H-FIRE technology in treating benign prostatic hyperplasia, Nosaier Medical remains committed to advancing its applications across broader therapeutic indications, delivering more safe and effective treatment options for patients. Moving forward, the company will further increase R&D investment to optimize product performance and advance the global healthcare landscape.

The success of H-FIRE technology represents not merely a therapeutic breakthrough, but a tangible commitment to patients' quality of life. We look forward to collaborating with more medical institutions to advance the adoption of this innovative technology, extending its revolutionary benefits to broader patient populations.